Maier, Sebastian H. ORCID: https://orcid.org/0000-0003-0120-8842; Schönecker, Stephan ORCID: https://orcid.org/0000-0003-0359-8960; Anagnostatou, Vasiliki ORCID: https://orcid.org/0009-0009-8438-2758; Garny, Sylvia; Nitschmann, Alexander ORCID: https://orcid.org/0009-0000-8620-2305; Fleischmann, Daniel F.; Büttner, Marcel; Kaul, David; Imhoff, Detlef ORCID: https://orcid.org/0000-0003-3627-7370; Fokas, Emmanouil; Seidel, Clemens ORCID: https://orcid.org/0000-0001-8178-5089; Hau, Peter; Kölbl, Oliver; Popp, Ilinca; Grosu, Anca-Ligia; Haussmann, Jan; Budach, Wilfried; Celik, Eren; Kahl, Klaus-Henning ORCID: https://orcid.org/0000-0002-0545-1367; Hoffmann, Elgin ORCID: https://orcid.org/0000-0002-9214-919X; Tabatabai, Ghazaleh; Paulsen, Frank; Holzgreve, Adrien ORCID: https://orcid.org/0000-0002-9566-8438; Albert, Nathalie L.; Mansmann, Ulrich ORCID: https://orcid.org/0000-0002-9955-8906; Corradini, Stefanie; Belka, Claus; Niyazi, Maximilian und Bodensohn, Raphael ORCID: https://orcid.org/0000-0002-1114-2771
(2024):
Dummy run for planning of isotoxic dose-escalated radiation therapy for glioblastoma used in the PRIDE trial (NOA-28; ARO-2024-01; AG-NRO-06).
In: Clinical and Translational Radiation Oncology, Bd. 47, 100790
[PDF, 10MB]
- Dokument bearbeiten